» Portfolio News

16.05.17

NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/KEYTRUDA® Phase 1/2 combination trial

Read more...

02.05.17

NOXXON PHARMA secures a private placement of €1 million and additional financing of up to €10 million through convertible notes with share subscritpion warrants attached to finance further clinical development of NOX-A12

Read more...

10.02.17

NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

Read more...

04.01.17

NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Read more...

15.12.16

NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda® (Pembrolizumab) in panacreatic and colorectal Cancer

Read more...